DigestRedComo funciona
Red
/
Empresas
Gi
No verificado

Gilead Sciences, Inc.

Sobre qué escribimos

BiotecnologíaFarmacéuticaMedicina - VariosSaludSanidad

98 Comunicados de prensa

Ver todos los comunicados de prensa
21/01/2026
Ciencia
Comunicación
Medicina - Varios
Sanidad
Farmacéutica
Salud
Oncología
Industria
New England Journal of Medicine Publishes Phase 3 ASCENT-04/KEYNOTE-D19 Results Supporting Trodelvy® Plus Keytruda® as a Potential New Standard of Care in First-line PD-L1+ Metastatic Triple-negative Breast Cancer
Fuente
Gilead Sciences, Inc.
Editor
Business Wire
1.00
0
22/12/2025
Web y redes sociales
Ferias y Congresos
Eventos
Biotecnología
Farmacéutica
Salud
Gilead Sciences to Present at Upcoming Investor Conference
Fuente
Gilead Sciences, Inc.
Editor
Business Wire
1.00
0
22/12/2025
Multimedia
Salud
VIH, SIDA y enfermedades autoinmunes
Sanidad
Farmacéutica
Biotecnología
Industria
Gilead Sciences Exercises Option to License Assembly Biosciences’ Helicase-Primase Inhibitor Programs for Recurrent Genital Herpes
Fuente
Gilead Sciences, Inc.
Editor
Business Wire
1.00
0
19/12/2025
Mercado laboral
Industria
VIH, SIDA y enfermedades autoinmunes
Sanidad
Política Nacional
Biotecnología
Farmacéutica
Salud
Gilead and U.S. Government Enter Agreement to Lower Costs of Medicines for Americans
Fuente
Gilead Sciences, Inc.
Editor
Business Wire
1.00
0
18/12/2025
Gilead Sciences Appoints Keeley Wettan as Executive Vice President, General Counsel, Legal & Compliance
Fuente
Gilead Sciences, Inc.
Editor
Business Wire
1.00
0
15/12/2025
Industria
VIH, SIDA y enfermedades autoinmunes
Salud
Sanidad
Medicina - Varios
Farmacéutica
Biotecnología
Gilead’s Investigational Single-Tablet Regimen of Bictegravir and Lenacapavir for HIV Treatment Meets Primary Endpoint in Phase 3 ARTISTRY-2 Trial
Fuente
Gilead Sciences, Inc.
Editor
Business Wire
1.00
0
09/12/2025
Industria
Oncología
Asociaciones/Profesionales
Salud
Sanidad
Farmacéutica
Biotecnología
Gilead Foundation Awards Over $3 Million to Support People Living With Metastatic Breast Cancer
Fuente
Gilead Sciences, Inc.
Editor
Business Wire
1.00
0
07/12/2025
Industria
Ciencia
Sanidad
Higiene alimentaria
Medicina - Varios
Biotecnología
Farmacéutica
Salud
Oncología
Yescarta® Delivers Consistent Safety, Efficacy, and Quality of Life Benefits Across Broad Range of Relapsed/Refractory Large B-cell Lymphoma Patients in New Analysis at ASH 2025
Fuente
Gilead Sciences, Inc.
Editor
Business Wire
1.00
0
06/12/2025
Industria
Biotecnología
Farmacéutica
Oncología
Sanidad
Salud
Medicina - Varios
Kite Announces New Data for Pivotal iMMagine-1 Study at ASH 2025, Highlighting Anito-cel’s Opportunity in Relapsed or Refractory Multiple Myeloma
Fuente
Gilead Sciences, Inc.
Editor
Business Wire
1.00
0
06/12/2025
Eventos
Industria
Oncología
Salud
Sanidad
Ciencia
Farmacéutica
Biotecnología
Kite’s Next-Generation Bicistronic CAR T-Cell Therapies Show Encouraging Phase 1 Results in Relapsed/Refractory B-Cell Lymphoma in New Data at ASH 2025
Fuente
Gilead Sciences, Inc.
Editor
Business Wire
1.00
0

Detalles de contacto

Redes sociales

Seguidores
0
Compatibilidad
0